Restricted accessResearch articleFirst published online 2017-08
Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver
Phosphorothioate (PS) modified antisense oligonucleotides (ASOs) have progressed rapidly in the clinic for treating a variety of disease indications. We previously demonstrated that the activity of PS ASOs in the liver can be enhanced by co-infusion of an excipient oligonucleotide (EON). It was posited that the EON saturates a nonproductive uptake pathway(s) thereby permitting accumulation of the PS ASO in a productive tissue compartment. In this report, we measured PS ASO activity following administration by bolus, infusion or co-fusion with EON within hepatocytes and nonparenchymal cells (NPCs), of the liver. This revealed that while ASOs accumulate preferentially in NPCs, they are intrinsically more active in hepatocytes. Furthermore, we show that the EON enhances ASO potency when infused up to 72 h before or after administration of the active ASO suggesting that the EON can saturate and displace the ASO from nonproductive to productive compartments. Physical presence of the EON in tissues was required for optimal potentiation suggesting that there is a dynamic distribution of the ASO and EON between the compartments. Lastly, using a candidate approach, we confirmed Stabilin-2 as a molecular pathway for ASO uptake in sinusoidal endothelial cells and the ASGR as a pathway for ASO uptake into hepatocytes in the liver.
Get full access to this article
View all access options for this article.
References
1.
BennettCF and SwayzeEE. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol, 50:259–293.
2.
BennettCF. (2007). Pharmacological properties of 2'-O-methoxyethyl-modified oligonucleotides. In: Antisense Drug Technology: Principles, Strategies and Applications. 2nd edn. CrookeST, ed. CRC Press, Boca Raton, pp 273–304.
BrownDA, KangSH, GryaznovSM, DeDionisioL, HeidenreichO, SullivanS, XuX and NerenbergMI. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem, 269:26801–26805.
5.
LiangX-H, SunH, ShenW and CrookeST. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res, 43:2927–2945.
6.
VickersTA and CrookeST. (2016). Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One, 11:e0161930.
7.
BeltingerC, SaragoviHU, SmithRM, LeSauteurL, ShahN, DeDionisioL, ChristensenL, RaibleA, JarettL and GewirtzAM. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest, 95:1814–1823.
8.
MillerCM, DonnerAJ, BlankEE, EggerAW, KellarBM, OstergaardME, SethPP and HarrisEN. (2016). Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res, 44:2782–2794.
9.
GearyRS, WancewiczE, MatsonJ, PearceM, SiwkowskiA, SwayzeEE and BennettCF. (2009). Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol, 78:284–291.
10.
KollerE, VincentTM, ChappellA, DeS, ManoharanM and BennettCF. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res, 39:4795–4807.
11.
GrahamMJ, CrookeST, MonteithDK, CooperSR, LemonidisKM, SteckerKK, MartinMJ and CrookeRM. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther, 286:447–458.
12.
SehgalA, VaishnawA and FitzgeraldK. (2013). Liver as a target for oligonucleotide therapeutics. J Hepatol, 59:1354–1359.
13.
GrahamMJ, CrookeST, LemonidisKM, GausHJ, TemplinMV and CrookeRM. (2001). Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol, 62:297–306.
14.
LiuW, HouY, ChenH, WeiH, LinW, LiJ, ZhangM, HeF and JiangY. (2011). Sample preparation method for isolation of single-cell types from mouse liver for proteomic studies. Proteomics, 11:3556–3564.
15.
ShemeshCS, YuRZ, GausHJ, GreenleeS, PostN, SchmidtK, MigawaMT, SethPP, ZanardiTA, et al. (2016). Pharmacokinetic and pharmacodynamic investigations of ION-353382, a model antisense oligonucleotide: Using alpha-2-macroglobulin and murinoglobulin double-knockout mice. Nucleic Acid Ther, 26:223–235.
16.
YuRZ, BakerB, ChappellA, GearyRS, CheungE and LevinAA. (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem, 304:19–25.
17.
MurrayS, IttigD, KollerE, BerdejaA, ChappellA, PrakashTP, NorrbomM, SwayzeEE, LeumannCJ and SethPP. (2012). TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues—a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res, 40:6135–6143.
18.
SethPP, VasquezG, AllersonCA, BerdejaA, GausH, KinbergerGA, PrakashTP, MigawaMT, BhatB and SwayzeEE. (2010). Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. J Org Chem, 75:1569–1581.
19.
SethPP, SiwkowskiA, AllersonCR, VasquezG, LeeS, PrakashTP, WancewiczEV, WitchellD and SwayzeEE. (2009). Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem, 52:10–13.
20.
HenrySP, GearyRS, YuR and LevinAA. (2001). Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs, 2:1444–1449.
21.
CrookeST, GrahamMJ, ZuckermanJE, BrooksD, ConklinBS, CumminsLL, GreigMJ, GuinossoCJ, KornbrustD, et al. (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther, 277:923–937.
WolfrumC, ShiS, JayaprakashKN, JayaramanM, WangG, PandeyRK, RajeevKG, NakayamaT, CharriseK, et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol, 25:1149–1157.
24.
ButlerM, CrookeRM, GrahamMJ, LemonidisKM, LougheedM, MurraySF, WitchellD, SteinbrecherU and BennettCF. (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther, 292:489–496.
25.
HarrisEN and WeigelPH. (2008). The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology, 18:638–648.
26.
PandeyMS, HarrisEN, WeigelJA and WeigelPH. (2008). the cytoplasmic domain of the hyaluronan receptor for endocytosis (HARE) contains multiple endocytic motifs targeting coated pit-mediated internalization. J Biol Chem, 283:21453–21461.
27.
PempeEH, XuY, GopalakrishnanS, LiuJ and HarrisEN. (2012). Probing structural selectivity of synthetic heparin binding to stabilin protein receptors. J Biol Chem, 287:20774–20783.
28.
SteirerLM, ParkEI, TownsendRR and BaenzigerJU. (2009). The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid α2,6-galactose. J Biol Chem, 284:3777–3783.
29.
NairJK, WilloughbyJL, ChanA, CharisseK, AlamMR, WangQ, HoekstraM, KandasamyP, Kel'inAV, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc, 13:16958–16961.
30.
PrakashTP, GrahamMJ, YuJ, CartyR, LowA, ChappellA, SchmidtK, ZhaoC, AghajanM, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res, 42:8796–8807.
31.
BijsterboschMK, ManoharanM, RumpET, De VruehRL, van VeghelR, TivelKL, BiessenEA, BennettCF, CookPD and van BerkelTJ. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res, 25:3290–3296.
32.
Falkowska-HansenB, FalkowskiM, MetharomP, KrunicD and GoerdtS. (2007). Clathrin-coated vesicles form a unique net-like structure in liver sinusoidal endothelial cells by assembling along undisrupted microtubules. Exp Cell Res, 313:1745–1757.
33.
KnolleP. (2007). Role and function of liver sinusoidal endothelial cells. In: Liver Immunology, GershwinME, VierlingJ, and MannsM, eds. Humana Press, Totowa, NJ, pp 25–39.
34.
YuRZ, LemonidisKM, GrahamMJ, MatsonJE, CrookeRM, TribbleDL, WedelMK, LevinAA, and GearyRS. (2009). Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol, 77:910–919.
35.
KinbergerGA, PrakashTP, YuJ, VasquezG, LowA, ChappellA, SchmidtK, MurrayHM, GausH, SwayzeEE and SethPP. (2016). Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorg Med Chem Lett, 26:3690–3693.
36.
SchmidtK, PrakashTP, DonnerAJ, KinbergerGA, GausHJ, LowA, OstergaardME, BellM, SwayzeEE and SethPP. (2017). Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Res DOI: 10.1093/nar/gkx060
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
